FDA reinforces safety information about serious low blood sugar levels and mental health side effects with fluoroquinolone antibiotics; requires label changes

Monday August 20, 2018

The Food and Drug Administration (FDA) is strengthening the current warnings in the prescribing information that fluoroquinolone antibiotics may cause significant decreases in blood sugar and certain mental health side effects. The low blood sugar levels can result in serious problems, including coma, particularly in older people and patients with diabetes who are taking medicines to reduce blood sugar. We are making these changes because our recent review found reports of life-threatening low blood sugar side effects and reports of additional mental health side effects.

Please click on the link bellow to review more on this topic:

https://www.fda.gov/Drugs/DrugSafety/ucm611032.htm

CMS Update: Requirements to Reduce Legionella Risk in Water Systems

Wednesday August 1, 2018

Center for Clinical Standards and Quality/Quality, Safety and Oversight Group

Ref: QSO -17-30- Hospitals/CAHs/NHs

DATE: June 02, 2017 REVISED 07.06.2018

TO: State Survey Agency Directors

FROM: Director

Quality, Safety and Oversight Group ( formerly Survey & Certification Group )

SUBJECT: Requirement to Reduce Legionella Risk in Healthcare Facility Water Systems to Prevent Cases and Outbreaks of Legionnaires' Disease (LD)

***Revised to Clarify Expectations for Providers, Accrediting Organizations, and Surveyors***

  https://www.cms.gov/Medicare/Provider-Enrollment-and-Certification/SurveyCertificationGenInfo/Downloads/QSO17-30-HospitalCAH-NH-REVISED-.pdf